 |
Conference papers
A phase II randomised, double-blind, placebo-controlled, proof of concept study of oral seletalisib in patients with primary Sjögren’s syndrome (PSS).
Maria Juárez 1 Nieves Diaz 1 Geoffrey I Johnston 1 Saba Nayar 2 Andrew Payne 1 Eric Helmer 1 Dionne Cain 1 Paulette Williams 3 Wan Fai Ng 4 Benjamin Fisher 2 Jacques-Eric Gottenberg 5 Giuliana Guggino 6 Xavier Mariette 7 Marika Kvarnström 8 Valérie Devauchelle-Pensec 9, 10 Jose Rosas 11 Juan Sanchez-Burson 12 Roberto Giacomelli 13 Francesca Barone 2 Simon J Bowman 14
Wan Fai Ng 4
Author
Benjamin Fisher 2
Author
ORCID : 0000-0003-4631-549X
Jacques-Eric Gottenberg 5
Author
ORCID : 0000-0002-9469-946X
Giuliana Guggino 6
Author
Xavier Mariette 7
Author
Marika Kvarnström 8
Author
Valérie Devauchelle-Pensec 9, 10
Author
Employer institution: Centre Hospitalier Régional Universitaire de Brest
Jose Rosas 11
Author
Juan Sanchez-Burson 12
Author
Roberto Giacomelli 13
Author
Francesca Barone 2
Author
IdHAL : francesca-baroneIdRef : 13162413X
Simon J Bowman 14
Author
1
UCB Pharma [Slough] (Slough, Berkshire - United Kingdom)
- UCB Pharma [Brussels] (Allée de la Recherche, 60 B - 1070 Brussels - Belgium)
2
University of Birmingham [Birmingham] (Edgbaston
Birmingham B15 2TT - United Kingdom)
3
UCB Pharma Raleigh (United States)
5
University Hospital of Strasbourg (France)
7
Service de rhumatologie (Le Kremlin-Bicêtre - France)
- UP11 - Université Paris-Sud - Paris 11 (Bâtiment 300 - 91405 Orsay cedex - France)
- AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) (France)
- Hôpital Bicêtre (France)
8
Department of Medicine - Unit of Experimental Rheumatology, Stockhom (Karolinska Institutet, Karolinska University Hospital Stockhom - Sweden)
9
CHU - BREST - Rhumato - CHRU Brest - Service de Rhumatologie (Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, 29200 Brest - France)
10
LBAI - Lymphocytes B, Autoimmunité et Immunothérapies (5 Foch - CHU Morvan - BP 824 - 29609 Brest - France - France)
- UBO - Université de Brest (Université de Bretagne Occidentale - 3 Rue des Archives 29238, Brest - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U1227 (101, rue de Tolbiac, 75013 Paris - France)
- LabEX IGO Immunothérapie Grand Ouest (France)
- Nantes Univ - Nantes Université (France)
- IBSAM - Institut Brestois Santé Agro Matière (Université de Brest- UBO
29238 Brest - France)
- UBO - Université de Brest (Université de Bretagne Occidentale - 3 Rue des Archives 29238, Brest - France)
11
Hospital Marina Baixa, Villajoyosa (Spain)
12
Infantaluisa Hospital, Sevilla (Spain)
13
UNIVAQ - University of L'Aquila [Italy] (UNIVERSITÀ DEGLI STUDI DE L'AQUILA / University of L'Aquila Via Giovanni Falcone 25, 67100 Coppito - Italy)
Document type :
Conference papers
Domain :
Complete list of metadata
https://hal.univ-brest.fr/hal-02150798
Contributor : Geneviève Michel Connect in order to contact the contributor
Submitted on : Friday, June 7, 2019 - 2:34:54 PM
Last modification on : Tuesday, November 29, 2022 - 5:10:07 PM
Contributor : Geneviève Michel Connect in order to contact the contributor
Submitted on : Friday, June 7, 2019 - 2:34:54 PM
Last modification on : Tuesday, November 29, 2022 - 5:10:07 PM
Identifiers
- HAL Id : hal-02150798, version 1
Collections
Citation
Maria Juárez, Nieves Diaz, Geoffrey I Johnston, Saba Nayar, Andrew Payne, et al.. A phase II randomised, double-blind, placebo-controlled, proof of concept study of oral seletalisib in patients with primary Sjögren’s syndrome (PSS).. EULAR 2019, Jun 2019, MADRID, Spain. ⟨hal-02150798⟩
Metrics
Record views